Equities Analysts Issue Forecasts for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Zacks Research reduced their Q1 2025 earnings estimates for shares of Exelixis in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings of $0.35 per share for the quarter, down from their previous forecast of $0.40. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.50 EPS, FY2025 earnings at $1.92 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.47 EPS.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Several other equities analysts have also commented on the stock. Citigroup upped their price objective on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Brookline Capital Management initiated coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. JMP Securities restated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. Finally, Piper Sandler upped their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Stock Performance

Shares of EXEL stock opened at $38.21 on Thursday. The firm’s 50 day moving average price is $34.81 and its 200-day moving average price is $31.91. Exelixis has a one year low of $20.14 and a one year high of $39.30. The firm has a market cap of $10.69 billion, a P/E ratio of 21.59, a P/E/G ratio of 1.13 and a beta of 0.57.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB grew its position in shares of Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 290 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 317 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 330 shares during the period. Covestor Ltd boosted its stake in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 341 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its stake in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock worth $1,937,000 after purchasing an additional 354 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Exelixis

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the transaction, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.